GlassScriptPhysician profile
Huy M Tran
NPI 1043251309
$11,455.59
in general payments reported to CMS, 2019-2025
27 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,710 · 2020: $1,011 · 2021: $1,017 · 2022: $1,219 · 2023: $1,980 · 2024: $1,272 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,498.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,030.69 | 2019-2024 | Tecnis Iol, One Series Ultra |
| Bausch & Lomb Americas INC. | $1,360.45 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $985.80 | 2019-2022 | |
| Abbvie INC. | $977.91 | 2022-2025 | Vuity, Durysta, Lumigan |
| Alcon Vision LLC | $965.63 | 2019-2025 | Tryptyr, Rocklatan, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $835.79 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $685.31 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $510.46 | 2019-2023 | |
| Dompe US, INC. | $339.32 | 2019-2025 | Oxervate |
| Astellas Pharma US INC | $303.86 | 2023-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $293.57 | 2019-2021 | |
| Harrow Eye, LLC | $282.78 | 2024-2025 | Vevye, Ilevro |
| Tarsus Pharmaceuticals, INC. | $238.98 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $219.33 | 2022-2023 | Tepezza |
| Ocular Therapeutix, INC. | $209.80 | 2023-2025 | Dextenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $194.27 | 2022-2023 | Tyrvaya |
| Sight Sciences, INC. | $192.78 | 2025 | Omni Surgical System, Tearcare System |
| Amgen INC. | $174.88 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $173.62 | 2020-2022 | |
| Shire North American Group INC | $132.07 | 2019 | |
| Thea Pharma INC. | $89.67 | 2023-2024 | Iyuzeh |
| Rxsight INC | $77.02 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
| Tearlab Corp | $67.00 | 2022 | |
| Biotissue Holdings INC. | $36.52 | 2019 | |
| Halozyme INC | $35.14 | 2024 | Hylenex Recombinant |
| Apellis Pharmaceuticals, INC. | $22.57 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $20.37 | 2025 | Rayone Emv, Rayone Spheric, Rayner Cataract Set 1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.